Navigation Links
Neurocrine Announces Top-Line Results of Corticotropin Releasing Factor Antagonist GSK561679 for Treatment of Major Depressive Disorder
Date:9/14/2010

SAN DIEGO, Sept. 14 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced top-line efficacy and safety results from a Phase II clinical trial utilizing Corticotropin Releasing Factor (CRF1) receptor antagonist GSK561679 in patients currently experiencing a major depressive episode.  This double-blind, placebo controlled trial randomized 150 patients into two treatment arms, 350 mg of GSK561679 daily and placebo, and was conducted in the United States by GlaxoSmithKline (GSK) under the GSK/Neurocrine CRF1 collaboration. The primary endpoint was change from baseline in the Bech Melancholia scale at Week 6 and a key secondary endpoint was change from baseline in the HAMD-17 scale at Week 6.

Results of statistical analysis using the intent-to-treat population revealed no benefit of GSK561679 compared with placebo on both the Bech Melancholia and HAMD-17 endpoints. The top-line results are based on the six week placebo-controlled portion of the study for the intent to treat population of 145 patients. From a safety perspective, there were no significant adverse events, and the drug was generally well tolerated.

"It is clear from this study that CRF1 remains a difficult drug target in the drive to improve current pharmaceutical therapies for depression," said Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences.  "We plan to meet with GSK in the coming months after the full clinical data set is complete to determine the next steps for the CRF depression program."

Three separate academic collaborative clinical trials are ongoing to evaluate the effects of GSK561679 in Post Traumatic Stress Disorder, anxiety and alcoholism.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the lar
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Neurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2010 Financial Results
2. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
3. Neurocrine Biosciences to Present at the Deutsche Bank 35th Annual Health Care Conference
4. Neurocrine Biosciences to Present at the 30th Annual Cowen & Co. Health Care Conference
5. Neurocrine Biosciences, Inc. Prices Common Stock Offering
6. Neurocrine Announces Proposed Public Offering of Common Stock
7. Neurocrine Advances VMAT2 Inhibitor Program
8. Neurocrine Biosciences to Present at the 21st Annual Piper Jaffray Health Care Conference
9. Neurocrine Biosciences Reports Third Quarter 2009 Results
10. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2009 Financial Results
11. Neurocrine Biosciences Presents Elagolix Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 UBM Medica US ... leading online community to help oncologists and other clinicians ... regarding the use of targeted therapies and immunotherapies, discusses ... and treatment.  Every September, Blood ... to raise awareness about blood cancers—helping to increase survival ...
(Date:9/19/2014)...  Alere Inc. (NYSE: ALR ), a ... today in support of President Barack Obama,s ... global leader in rapid diagnostics for infectious disease, we ... address the serious threat of antibiotic resistance. We look ... initiatives to promote the development of rapid point-of-care tests ...
(Date:9/19/2014)... and ORLANDO, Fla. , Sept. ... Inspire therapy continues to grow, with the publication of ... on-line in Otolaryngology – Head and Neck ... a worsening of both objective and subjective measures of ... attribute Inspire therapy for the reduction in obstructive sleep ...
Breaking Medicine Technology:OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4
... SAN DIEGO, Sept. 15 Volcano Corporation (Nasdaq: ... $100 million aggregate principal amount of 2.875 percent convertible senior ... of 1933, as amended. Prior to June 1, 2015, the ... holders will receive up to the principal amount of the ...
... A new study conducted by Dobson | DaVanzo & ... durable medical equipment (DME) may limit Medicare beneficiaries, access ... the quality of products that Medicare consumers rely on. ... of millions of Americans who require oxygen equipment and ...
Cached Medicine Technology:Volcano Corporation Prices $100 Million 2.875 Percent Convertible Senior Notes Due 2015 2Volcano Corporation Prices $100 Million 2.875 Percent Convertible Senior Notes Due 2015 3Volcano Corporation Prices $100 Million 2.875 Percent Convertible Senior Notes Due 2015 4Volcano Corporation Prices $100 Million 2.875 Percent Convertible Senior Notes Due 2015 5Independent Study Concludes Medicare 'Competitive' Bidding Program for Durable Medical Equipment Could Negatively Affect Care Access, Quality, and Choice for Seniors and People with Disabilities 2Independent Study Concludes Medicare 'Competitive' Bidding Program for Durable Medical Equipment Could Negatively Affect Care Access, Quality, and Choice for Seniors and People with Disabilities 3Independent Study Concludes Medicare 'Competitive' Bidding Program for Durable Medical Equipment Could Negatively Affect Care Access, Quality, and Choice for Seniors and People with Disabilities 4
(Date:9/19/2014)... (PRWEB) September 19, 2014 "I have ... getting wrinkles due to stretching the skin around my ... Ala. "This inspired me to design a more convenient ... CONTACT LENS SYSTEM provides a quicker, easier, more sanitary ... need to perform this task manually, saves time and ...
(Date:9/19/2014)... 2014 -- Recent two-generation approaches to reducing poverty ... increasing attention from researchers, advocates, and foundations. By ... them to move to jobs that offer a ... and education for children, these programs aim to ... according to a new report from the National ...
(Date:9/19/2014)... (HealthDay News) -- When it comes to firearm deaths, ... States, while the District of Columbia has the highest, ... deaths from gun-related violence -- including murders, suicides and ... the study revealed. Hawaii,s rate was roughly three per ... the District of Columbia had the highest rate of ...
(Date:9/19/2014)... Medical College of Wisconsin (MCW) scientists has identified a new ... mice and in humans. The findings are published in the ... Leah Solberg Woods, Ph.D., associate professor of pediatrics at MCW ... Institute, led the study and is the corresponding author of ... gene called Tpcn2 in which a variant was associated with ...
(Date:9/19/2014)... Top10BestSEOHosting.com today compares many professional Windows web hosting ... are the best suppliers of 2014. Clients who ... VPS and cloud hosting) at affordable rates can ... HostMonster ( http://www.hostmonster.com/track/seohosts ) helps business companies and ... the cost. As a top rated hosting provider, ...
Breaking Medicine News(10 mins):Health News:A two generation lens: Current state policies fail to support families with young children 2Health News:U.S. Gun Deaths Lowest in Hawaii, Highest in D.C. 2Health News:Top10BestSEOHosting.com: They Are Best Windows Web Hosting Suppliers Of 2014 2
... use trends , , TUESDAY, March 4 (HealthDay News) -- When ... to give up the habit if it isn,t considered cool, ... research shows. , The findings will give prevention researchers ... embrace of illegal drugs, said study author Michelle Little, a ...
... to Take Action Against This Leading ... Cause of Home-Related Deaths, WASHINGTON, ... poisoning is the second leading,cause of home injury death in the ... one percent of U.S. adults ranked poisoning at the,top of the ...
... Estate Developer,s Foundation to Lead the ... in Ending Global Hunger, Improving Nutrition, NEW YORK, ... pledged a $15 million challenge grant to transform The ... Sciences in Rehovot, Israel. The gift will be the ...
... received a five-year, $20.5 million grant from the Bill ... investigating the biological factors underlying immune system control of ... provides support to the International HIV Controllers Study, which ... and has the overall goal of discovering information that ...
... Award and Massachusetts again takes ... top e-Prescribing State Honors, ... the leader in hosted services for email encryption and,e-prescribing, today ... 2008, for building awareness of improving,patient safety at the local ...
... AUSTIN, TX and TORONTO, March 4 /PRNewswire/ - ... dosing of healthy subjects in,a Phase I study ... from its,novel class of fatty acid biosyntheis inhibitors. ... and pharmacokinetics of a single,escalating oral dose. Affinium ...
Cached Medicine News:Health News:Troubled Boys Will Abandon Pot When It's Deemed Uncool 2Health News:New Home Safety Council(R) Research Shows the Majority of Families Underestimate the Danger of Poisoning Exposure at Home 2Health News:New Home Safety Council(R) Research Shows the Majority of Families Underestimate the Danger of Poisoning Exposure at Home 3Health News:New Home Safety Council(R) Research Shows the Majority of Families Underestimate the Danger of Poisoning Exposure at Home 4Health News:Robert H. Smith 'Feeding the Future' with $15 Million Gift to Hebrew University of Jerusalem 2Health News:Mass. General Hospital receives Gates Foundation grant to expand HIV controllers study 2Health News:Mass. General Hospital receives Gates Foundation grant to expand HIV controllers study 3Health News:Zix Corporation Celebrates National Patient Safety Awareness Week with Continued Success in e-Prescribing 2Health News:Zix Corporation Celebrates National Patient Safety Awareness Week with Continued Success in e-Prescribing 3Health News:Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic 2
... was the first device ... after diagnostic and interventional ... It is a collagen-based ... for immediate sheath removal ...
... VasoSeal VHD was ... rapidly stop bleeding after ... and radiology procedures. It ... sealing device approved for ...
InterVascular HemaPatch product line offers the vascular surgeon a range of collagen coated patches in a range of larger sizes angioplasty, or profundaplasty procedures without suture hole bleeding. ...
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
Medicine Products: